by John BIERS NEW YORK, United States (AFP) — Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation. Pfizer, whose vaccinee developed with German company BioNTech was the first approved in the United States to counter the deadly virus, sees slightly lower 2022 revenues for the vaccine compared with […]